Revision history of "Secondline cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma any subgroup analysis of the phase Three Heavenly demo"

From EECH Central
Jump to: navigation, search

Diff selection: Mark the radio boxes of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

  • (cur | prev) 12:45, 30 March 2024‎ Burstmargin41 (Talk | contribs)‎ . . (3,865 bytes) (+3,865)‎ . . (Created page with "Structural as well as organizational specifications of 310 divisions (cSCs Forty two.6%) ended up taken out. Median TTE price had been 63.3% (IQR 22 [https://www.selleckchem.c...")
Retrieved from "http://eechcentral.simhq.com/index.php?title=Secondline_cabozantinib_after_sorafenib_treatment_for_advanced_hepatocellular_carcinoma_any_subgroup_analysis_of_the_phase_Three_Heavenly_demo"